Correlation between Subfoveal Choroidal Thickness and Disease Activity in Wet Age-Related Macular Degeneration Using Spectral Domain Optical Coherence Tomography

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Aya Raafat Abouelregal ◽  
Alaa Fathy Mahmoud ◽  
Tamer Fahmy Eliwa ◽  
Karim Magdi Naguib
Keyword(s):  
Macular Degeneration ◽  
Choroidal Thickness ◽  
Age Related Macular Degeneration ◽  
Spectral Domain ◽  
Control Group ◽  
P Value ◽  
Neovascular Amd ◽  
Subfoveal Choroidal Thickness ◽  
Age Related ◽  
Significant Difference

Abstract Background Age-related macular degeneration (AMD) is the leading cause of severe irreversible visual impairment worldwide. The disease has a deep impact on the quality of life of affected person and represents a major socioeconomic challenge. Neovascular age-related macular degeneration (nAMD) is a rapidly progressing disease which impacts central vision. It is responsible for 90% of cases of AMD associated severe vision loss. Choroidal thicknening is hypothesized to occur in the active phase of neovascular AMD. On the other hand, multiple studies reported progressive choroidal thinning in nAMD. Aim to study the correlation between choroidal thickness, and the activity of choroidal neovascularization in cases of neovascular (wet) Age related macular degeneration using Spectral domain Ocular coherence tomography. Methodology Our study included 33 eyes of 30 participants subdivided into neovascular AMD group (23 eyes of 20 patients), and age matched control group (10 eyes of 10 participants). Spectral domain optical coherence tomography (Avanti RTVue XR AngioVue OCT (Optovue Inc, Fremont, USA) was used to measure central foveal thickness (CFT), and subfoveal choroidal thickness (SFCT) after conduction of complete ocular examination and history taking. Results Our study shows a significant decrease in subfoveal choroidal thickness in neovascular AMD group (157.82 + 68.67 µm) when compared to the age matched control group (266.9+ 48.37 µm) with (P value <0.001). But, we found no clinically significant difference in SFCT between active CNV (179.23 + 64.36 µm) and inactive CNV groups (136.4 + 72.97 µm) (P value = 0.19). Conclusion there is a significant thinning of choroid in nAMD in comparison to control. But no statistically significant difference in SFCT between active and inactive choroidal neovascular groups.

scholarly journals Assessment of Subfoveal Choroidal Thickness with SD-OCT in Eyes with Different Stages of Age-Related Macular Degeneration (AMD)

2021 ◽  
pp. 6-17
Author(s):  
E. Pateras ◽  
G. Kalogeropoulou
Keyword(s):  
Choroidal Thickness ◽  
Personal Data ◽  
Age Related Macular Degeneration ◽  
Spectral Domain ◽  
Enhanced Depth Imaging ◽  
Neovascular Amd ◽  
Subfoveal Choroidal Thickness ◽  
Spectral Domain Oct ◽  
Age Related ◽  
Group 2

Purpose: The aim of the study was to compare the subfoveal choroidal thickness (SFCT) with the use of Spectral-Domain OCT in eyes with AMD of different stages. Methods: The participants comprised of 30 age-matched normal eyes as controls (Group 1), 19 with early-AMD eyes (Group 2), 14 with intermediate-AMD eyes (Group 3) and 29 with advanced (neovascular) AMD eyes (Group 4). All subjects underwent routine ophthalmologic examination. The choroid images, which included the subfoveal choroidal thickness images, obtained using Spectral-Domain Optical Coherence Tomography (and the technique of Enhanced Depth Imaging-EDI). All of the participants volunteered in this study and remained anonymous due to the protection of their personal data. Results: 92 eyes with age greater than 65 years old were included. The mean subfoveal choroidal thickness was 260.93 ± 46.54 μm in age-matched normal eyes, 255.10 ± 44.85 μm in early AMD eyes, 230.92 ± 45.70 μm in intermediate AMD eyes and 206.82 ± 44.43 μm in advanced (neovascular) AMD eyes. There were statistically significant differences in the measurement results between the 4th Group with the 1st Group (P<0.0001) and 2nd Group (P=0.0006) respectively, meaning that SFCT was greater in normal and early AMD eyes. Conclusion: Decreasing subfoveal choroidal thickness was demonstrated in the progression of AMD, especially in the advanced AMD eyes compared to normal or early AMD eyes.

scholarly journals Effect of Ranibizumab Treatment in Cases of Choroidal Neovascular Membranes Secondary to Pathological Myopia versus Age-Related Macular Degeneration

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
M S Abdaltawab ◽  
Z F Ismail ◽  
W M A Ebeid ◽  
S M Fawzy
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Intravitreal Injections ◽  
P Value ◽  
Newly Diagnosed ◽  
Pathological Myopia ◽  
Age Related ◽  
Significant Difference ◽  
The Mean

Abstract Aim of the Work The aim of this work is to compare the response of treatment with ranibizumab in terms of visual acuity in cases of CNV secondary to pathological myopia versus CNV secondary to age-related macular degeneration. Methods This prospective, comparative study included ten eyes newly diagnosed as having CNV secondary to pathological myopia, and 10 eyes newly diagnosed as having subfoveal active CNV secondary to AMD. All patients had 3 monthly intravitreal Injections of 0.50 mg (in 0.05 ml of solution) ranibizumab with monthly evaluation of best corrected visual acuity (BCVA) by Landolt C chart, and also calculated in Logarithm of Minimum Angle of Resolution (Log MAR). Results pretreatment there was no significant difference between the two groups as the mean VA (Log Mar) was 1.31 ± 0.2 in AMD group and 1.17 ± 0.3 in MCNV group of P value = 0.431 and also post three IVI of ranibizumab showed no significant difference between the two groups as the mean VA (Log Mar) was 1.22 ± 0.2 for AMD and 1.22 ± 0.5 for MCNV of P value = 0.635. Conclusion there was no significant difference in BCVA between AMD and MCNV groups after three intravitreal injections of ranibizumab.

Increased levels of circulating CD34+ cells in neovascular age-related macular degeneration: relation with clinical and OCT features

2018 ◽  
Vol 28 (1) ◽  
pp. 80-86
Author(s):  
Caner Kara ◽  
Pınar Ç. Özdal ◽  
Emrullah Beyazyıldız ◽  
Nurgül E. Özcan ◽  
Mehmet Y. Teke ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Control Group ◽  
Study Group ◽  
Control Groups ◽  
Age Related ◽  
Significant Difference ◽  
And Control

Purpose: To investigate the levels of circulating CD34+ stem cells in patients with neovascular type age-related macular degeneration (AMD) and its relation with clinical and optical coherence tomography (OCT) findings. Methods: The study consisted of 55 patients: 28 patients (18 male and 10 female) with neovascular type AMD as a study group and 27 patients (12 male and 15 female) scheduled for cataract surgery as a control group. The level of CD34+ stem cells was measured by flow cytometry. Demographic and clinical data were recorded. Results: The mean ages of patients in the study and control groups were 71 ± 8 and 68 ± 6 years, respectively. There was no statistically significant difference in terms of age, sex, or systemic disease association between study and control groups. However, smoking status was significantly higher in the study group (67.9% vs 37.0%; p = 0.02). Stem cell levels were significantly higher in the study group (1.5 ± 0.9 vs 0.5 ± 0.3; p<0.001), but there was no relation between stem cell levels and clinical and OCT findings. Conclusions: Increased circulating CD34+ stem cell levels were observed in patients with choroidal neovascular membrane associated with AMD, but no significant relation was found between cell levels and clinical and OCT findings.

Sign in / Sign up

Export Citation Format

Share Document